Fear of cancer recurrence therapy (FORT): A randomized controlled trial.
Christine Maheu(University Health Network), Rajvi J. Wani(McGill University), Cheryl Harris(University of Ottawa), Christina Tomei(University of Ottawa), Lynne Jolicoeur(Ottawa Hospital), Brittany Mutsaers(University of Ottawa), Agnihotram V. Ramanakumar(McGill University Health Centre), Lorena Baku(University of Waterloo), Maude Hébert(Université du Québec à Trois-Rivières), Scott Secord(Canadian Partnership Against Cancer), Nancy Drummond(Jewish General Hospital), Linda Muraca(Mount Sinai Hospital), Monique Lefèbvre(Ottawa Hospital), Frederic Lamonde(McGill University Health Centre), Sarah Ferguson(Princess Margaret Cancer Centre), Christine Courbasson, Joanne Power(McGill University Health Centre), Lori J. Bernstein(St. Michael's Hospital), Mina Singh(York University), Sophie Lebel(University of Ottawa)
Cited by 40
Related Papers
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
|The Lancet Oncology|2019|1k
What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis
|Psycho-Oncology|2022|295
Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice
|Annals of Oncology|2013|250
Psychometric Properties of the Tampa Scale for Kinesiophobia-11 (TSK-11)
|Journal of Pain|2012|229